Mazdutide Trial Registered for AFib Recurrence After Ablation

A clinical trial listing for mazdutide was registered, dated October 27, 2026. The study is titled "Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients." Its identifier is NCT07897305. The trial phase is listed as not applicable. According to the registry, the study status is not yet recruiting. This means participant enrollment has not yet begun as of the listed date. No results or outcome data have been reported for this trial at this time. Mazdutide remains classified as an unapproved compound currently under research investigation. The trial aims to examine mazdutide's role specifically in obese patients who have undergone catheter ablation for atrial fibrillation. No efficacy, safety outcomes, or comparative data are included in this registration update. Further details on trial design, recruitment timelines, and planned endpoints may become available as the study progresses toward its recruiting phase. Readers interested in this compound can find additional background information on the mazdutide compound overview page.